However, with the successful development of gene therapy for retinal dystrophies, such as for Leber congenital amaurosis due to RPE65 mutations [25-27], molecular diagnosis is of increasing importance to enroll patients in future clinical trials. This evidence concerns the gene RPE65 and Leber congenital amaurosis.